Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment

MW. Saif, CR. Becerra, MG. Fakih, W. Sun, L. Popovic, S. Krishnamurthi, TJ. George, MA. Rudek, DR. Shepard, J. Skopek, V. Sramek, B. Zaric, I. Yamamiya, KA. Benhadji, K. Hamada, Y. He, L. Rosen

. 2021 ; 88 (3) : 485-497. [pub] 20210607

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, fáze I, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003790
E-zdroje Online Plný text

NLK ProQuest Central od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-02-01 do Před 1 rokem
Public Health Database (ProQuest) od 1997-02-01 do Před 1 rokem

Odkazy

PubMed 34097100
DOI 10.1007/s00280-021-04308-z
Knihovny.cz E-zdroje

PURPOSE: Trifluridine/tipiracil (FTD/TPI) is approved for advanced colorectal and gastric/gastroesophageal cancer; however, data in patients with renal impairment (RI) are limited. This phase I study evaluated FTD/TPI in patients with advanced solid tumors and varying degrees of RI to develop dosing guidance. METHODS: Patients were enrolled into normal renal function (CrCl ≥ 90 mL/min), mild RI (CrCl 60-89 mL/min), or moderate RI (CrCl 30-59 mL/min) cohorts and administered the recommended FTD/TPI dose (35 mg/m2 twice daily, days 1-5 and 8-12; 28-day cycle). Based on interim pharmacokinetics/safety data, patients with severe RI (CrCl 15-29 mL/min) were enrolled and received FTD/TPI 20 mg/m2 twice daily. RESULTS: Forty-three patients (normal renal function [n = 12]; mild RI [n = 12]; moderate RI [n = 11]; severe RI [n = 8]) were enrolled and treated. At steady state, compared to values in patients with normal renal function, FTD area under the curve (AUC) was not significantly different in patients with RI, but TPI AUC was significantly higher and increased with RI severity. FTD/TPI safety profile was consistent with prior experience, but grade ≥ 3 adverse events (AEs) were more frequent in the RI cohorts (83.3% [mild], 90.9% [moderate], 75.0% [severe], and normal [50.0%]). Hematologic AEs (anemia and neutropenia) were more frequent with RI. Overall, seven patients discontinued because of unrelated, nonhematologic AEs. CONCLUSION: FTD/TPI is safe and tolerable at the recommended 35 mg/m2 dose in patients with mild/moderate RI and at the reduced 20 mg/m2 dose in patients with severe RI. TRIAL REGISTRATION: NCT02301117, registration date: November 21, 2014.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003790
003      
CZ-PrNML
005      
20220127145848.0
007      
ta
008      
220113s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00280-021-04308-z $2 doi
035    __
$a (PubMed)34097100
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Saif, Muhammad Wasif $u Medical Oncology, Northwell Health Cancer Institute, 1111 Marcus Avenue, Suite 216, Lake Success, NY, 11042, USA. wsaif@northwell.edu
245    12
$a A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment / $c MW. Saif, CR. Becerra, MG. Fakih, W. Sun, L. Popovic, S. Krishnamurthi, TJ. George, MA. Rudek, DR. Shepard, J. Skopek, V. Sramek, B. Zaric, I. Yamamiya, KA. Benhadji, K. Hamada, Y. He, L. Rosen
520    9_
$a PURPOSE: Trifluridine/tipiracil (FTD/TPI) is approved for advanced colorectal and gastric/gastroesophageal cancer; however, data in patients with renal impairment (RI) are limited. This phase I study evaluated FTD/TPI in patients with advanced solid tumors and varying degrees of RI to develop dosing guidance. METHODS: Patients were enrolled into normal renal function (CrCl ≥ 90 mL/min), mild RI (CrCl 60-89 mL/min), or moderate RI (CrCl 30-59 mL/min) cohorts and administered the recommended FTD/TPI dose (35 mg/m2 twice daily, days 1-5 and 8-12; 28-day cycle). Based on interim pharmacokinetics/safety data, patients with severe RI (CrCl 15-29 mL/min) were enrolled and received FTD/TPI 20 mg/m2 twice daily. RESULTS: Forty-three patients (normal renal function [n = 12]; mild RI [n = 12]; moderate RI [n = 11]; severe RI [n = 8]) were enrolled and treated. At steady state, compared to values in patients with normal renal function, FTD area under the curve (AUC) was not significantly different in patients with RI, but TPI AUC was significantly higher and increased with RI severity. FTD/TPI safety profile was consistent with prior experience, but grade ≥ 3 adverse events (AEs) were more frequent in the RI cohorts (83.3% [mild], 90.9% [moderate], 75.0% [severe], and normal [50.0%]). Hematologic AEs (anemia and neutropenia) were more frequent with RI. Overall, seven patients discontinued because of unrelated, nonhematologic AEs. CONCLUSION: FTD/TPI is safe and tolerable at the recommended 35 mg/m2 dose in patients with mild/moderate RI and at the reduced 20 mg/m2 dose in patients with severe RI. TRIAL REGISTRATION: NCT02301117, registration date: November 21, 2014.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a anemie $x chemicky indukované $x epidemiologie $7 D000740
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000971
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a kohortové studie $7 D015331
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nemoci ledvin $x patofyziologie $7 D007674
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a neutropenie $x chemicky indukované $x epidemiologie $7 D009503
650    _2
$a pyrrolidiny $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D011759
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a thymin $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D013941
650    _2
$a trifluridin $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D014271
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Becerra, Carlos R $u Texas Oncology, Baylor University Medical Center, Dallas, TX, USA
700    1_
$a Fakih, Marwan G $u City of Hope Comprehensive Cancer Center, Duarte, CA, USA
700    1_
$a Sun, Weijing $u Division of Oncology, University of Kansas Medical Center, Kansas City, KS, USA
700    1_
$a Popovic, Lazar $u Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia
700    1_
$a Krishnamurthi, Smitha $u Cleveland Clinic, Cleveland, OH, USA
700    1_
$a George, Thomas J $u University of Florida Health Cancer Center, Gainesville, FL, USA
700    1_
$a Rudek, Michelle A $u Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
700    1_
$a Shepard, Dale R $u Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Skopek, Jiri $u Thomayer Hospital Prague and Department of Biophysics and Informatics, First Medical Faculty, Prague, Czech Republic
700    1_
$a Sramek, Vladimir $u Fakultni Nemocnice u Sv. Anny v Brně, Anesteziologicko Resustitační Klinika, Brno, Czech Republic
700    1_
$a Zaric, Bojan $u Institute for Pulmonary Diseases of Vojvodina, University of Novi Sad, Novi Sad, Serbia
700    1_
$a Yamamiya, Ikuo $u Taiho Oncology, Inc., Princeton, NJ, USA
700    1_
$a Benhadji, Karim A $u Taiho Oncology, Inc., Princeton, NJ, USA
700    1_
$a Hamada, Kensuke $u Taiho Oncology, Inc., Princeton, NJ, USA
700    1_
$a He, Yaohua $u Taiho Oncology, Inc., Princeton, NJ, USA
700    1_
$a Rosen, Lee $u Division of Hematology-Oncology, University of California, Los Angeles, CA, USA
773    0_
$w MED00001040 $t Cancer chemotherapy and pharmacology $x 1432-0843 $g Roč. 88, č. 3 (2021), s. 485-497
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34097100 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145844 $b ABA008
999    __
$a ok $b bmc $g 1751295 $s 1154939
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 88 $c 3 $d 485-497 $e 20210607 $i 1432-0843 $m Cancer chemotherapy and pharmacology $n Cancer Chemother Pharmacol $x MED00001040
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace